An overview of current and emerging devices for percutaneous left atrial appendage closure
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
An overview of current and emerging devices for percutaneous left atrial appendage closure. / Chow, Danny H F; Wong, Yam-Hong; Park, Jai-Wun; Lam, Yat-Yin; De Potter, Tom; Rodés-Cabau, Josep; Asmarats, Lluis; Sandri, Marcus; Sideris, Eleftherios; McCaw, Trevor; Lee, Randall J; Sievert, Horst; Søndergaard, Lars; De Backer, Ole.
I: Trends in Cardiovascular Medicine, Bind 29, Nr. 4, 2019, s. 228-236.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - An overview of current and emerging devices for percutaneous left atrial appendage closure
AU - Chow, Danny H F
AU - Wong, Yam-Hong
AU - Park, Jai-Wun
AU - Lam, Yat-Yin
AU - De Potter, Tom
AU - Rodés-Cabau, Josep
AU - Asmarats, Lluis
AU - Sandri, Marcus
AU - Sideris, Eleftherios
AU - McCaw, Trevor
AU - Lee, Randall J
AU - Sievert, Horst
AU - Søndergaard, Lars
AU - De Backer, Ole
N1 - Copyright © 2018 Elsevier Inc. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.
AB - Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.
KW - Animals
KW - Atrial Appendage/physiopathology
KW - Atrial Fibrillation/complications
KW - Cardiac Catheterization/adverse effects
KW - Equipment Design
KW - Humans
KW - Risk Factors
KW - Stroke/diagnosis
KW - Treatment Outcome
U2 - 10.1016/j.tcm.2018.08.008
DO - 10.1016/j.tcm.2018.08.008
M3 - Review
C2 - 30205924
VL - 29
SP - 228
EP - 236
JO - Trends in Cardiovascular Medicine
JF - Trends in Cardiovascular Medicine
SN - 1050-1738
IS - 4
ER -
ID: 233727736